Next Article in Journal
Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination—Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay
Previous Article in Journal
Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
Previous Article in Special Issue
Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
 
 
Article

Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants

1
Beijing Institute of Biological Products Company Limited, Beijing 100176, China
2
China National Biotec Group Company Limited, Beijing 100024, China
3
College of Life Sciences and Biotechnology, Beijing University of Technology, Beijing 100021, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Giuseppe La Torre
Vaccines 2022, 10(8), 1208; https://doi.org/10.3390/vaccines10081208
Received: 8 June 2022 / Revised: 20 July 2022 / Accepted: 26 July 2022 / Published: 29 July 2022
(This article belongs to the Special Issue Advances in COVID-19 Vaccines Development)
Since the beginning of the COVID-19 pandemic, numerous variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged, including five variants of concern (VOC) strains listed by the WHO: Alpha, Beta, Gamma, Delta and Omicron. Extensive studies have shown that most of these VOC strains, especially the currently dominant variant Omicron, can escape the host immune response induced by existing COVID-19 vaccines to different extents, which poses considerable risk to the health of human beings around the world. In the present study, we developed a vaccine based on inactivated SARS-CoV-2 and an adjuvant consisting of aluminum hydroxide (alum) and CpG. The immunogenicity and safety of the vaccine were investigated in rats. The candidate vaccine elicited high titers of SARS-CoV-2-spike-specific IgG antibody and neutralizing antibody in immunized rats, which not only neutralize the original SARS-CoV-2, but also showed great cross-neutralization activity against the Beta, Delta and Omicron variants. View Full-Text
Keywords: CpG; SARS-CoV-2; Omicron; inactivated vaccine; immunogenicity; safety CpG; SARS-CoV-2; Omicron; inactivated vaccine; immunogenicity; safety
Show Figures

Figure 1

MDPI and ACS Style

Zhang, Y.; Zheng, X.; Sheng, W.; Liang, H.; Zhao, Y.; Zhu, X.; Yang, R.; Zhang, Y.; Dong, X.; Li, W.; Pei, F.; Ding, L.; Chang, Z.; Deng, L.; Yuan, G.; Yang, Z.; Zhu, D.; Yang, X.; Wang, H. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. Vaccines 2022, 10, 1208. https://doi.org/10.3390/vaccines10081208

AMA Style

Zhang Y, Zheng X, Sheng W, Liang H, Zhao Y, Zhu X, Yang R, Zhang Y, Dong X, Li W, Pei F, Ding L, Chang Z, Deng L, Yuan G, Yang Z, Zhu D, Yang X, Wang H. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. Vaccines. 2022; 10(8):1208. https://doi.org/10.3390/vaccines10081208

Chicago/Turabian Style

Zhang, Yuntao, Xiaotong Zheng, Wang Sheng, Hongyang Liang, Yuxiu Zhao, Xiujuan Zhu, Rong Yang, Yadan Zhang, Xiaofei Dong, Weidong Li, Fei Pei, Ling Ding, Zhen Chang, Li Deng, Guangying Yuan, Zhaona Yang, Di Zhu, Xiaoming Yang, and Hui Wang. 2022. "Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants" Vaccines 10, no. 8: 1208. https://doi.org/10.3390/vaccines10081208

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop